Efficacy and Tolerability of Sodium Zirconium Cyclosilicate or Patiromer in Managing Hyperkalemia: A Systematic Review and Meta-Analysis - PubMed
7 hours ago
- #patiromer
- #SZC
- #hyperkalemia
- Sodium zirconium cyclosilicate (SZC) and patiromer are approved for hyperkalemia treatment.
- SZC significantly reduces serum potassium levels within 48-72 hours.
- Both SZC and patiromer effectively lower serum potassium by the end of treatment.
- SZC normalizes serum potassium and reduces hyperkalemia incidence.
- Patiromer supports RAAS inhibitor optimization by enabling target dosing and reducing discontinuation.
- SZC is associated with a higher incidence of edema.
- Patiromer is linked to increased rates of constipation and hypokalemia.
- Therapy selection should consider treatment goals and individual patient risks.